Clinical trial
Antimalarial Drug Resistance in Mali
NCT00127998 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00127998 |
|---|---|
| Title | Antimalarial Drug Resistance in Mali |
| Official title | Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Malaria Research and Training Center, Bamako, Mali |
| Status | Completed |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Drug |
| Interventions | chloroquine, sulfadoxine-pyrimethamine, amodiaquine, amodiaquine+artesunate, amodiaquine+sulfadoxine-pyrimethamine, sulfadoxine-pyrimethamine+artesunate, artemether-lumefantrine, mefloquine |
| Enrollment | 1,011 |
| Start date | Jul 1, 2005 |
| First posted | Aug 9, 2005 |
| Last update posted | Aug 16, 2006 |
| Countries | Mali |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: